S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13

Intra-Cellular Therapies Stock Forecast, Price & News

-1.91 (-3.35%)
(As of 07/1/2022 05:43 PM ET)
Today's Range
50-Day Range
52-Week Range
896,500 shs
Average Volume
1.04 million shs
Market Capitalization
$5.20 billion
P/E Ratio
Dividend Yield
Price Target

Intra-Cellular Therapies Stock Forecast (MarketRank)

Analyst Rating
Moderate Buy
2.88 Rating Score
12.8% Upside
$62.25 Price Target
Short Interest
8.13% of Float Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
Insider Trading
Selling Shares
$6.11 M Sold Last Quarter
Proj. Earnings Growth
From ($2.95) to ($1.28) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

2.21 out of 5 stars

Medical Sector

623rd out of 1,429 stocks

Pharmaceutical Preparations Industry

284th out of 682 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive ITCI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Intra-Cellular Therapies and its competitors with MarketBeat's FREE daily newsletter.

Intra-Cellular Therapies logo

About Intra-Cellular Therapies (NASDAQ:ITCI)

Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in developing lumateperone, which is in Phase III clinical trial for the treatment of bipolar depression, as well as to treat autism spectrum disorder; and in additional neuropsychiatric indications, such as sleep disorders associated with neuropsychiatric and neurological disorders. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease and heart failure; ITI-1284-ODT-SL for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.

ITCI Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Price Target and Rating

Average Stock Price Forecast
High Stock Price Forecast
Low Stock Price Forecast
Forecasted Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
8 Analysts


Net Income
$-284.13 million
Net Margins
Pretax Margin


Sales & Book Value

Annual Sales
$83.80 million
Book Value
$5.13 per share


Free Float
Market Cap
$5.20 billion

Intra-Cellular Therapies Frequently Asked Questions

Should I buy or sell Intra-Cellular Therapies stock right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intra-Cellular Therapies in the last twelve months. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" Intra-Cellular Therapies stock.
View analyst ratings for Intra-Cellular Therapies
or view top-rated stocks.

What is Intra-Cellular Therapies' stock price forecast for 2022?

8 equities research analysts have issued 1 year price targets for Intra-Cellular Therapies' stock. Their ITCI stock forecasts range from $40.00 to $75.00. On average, they expect Intra-Cellular Therapies' stock price to reach $62.25 in the next twelve months. This suggests a possible upside of 12.8% from the stock's current price.
View analysts' price targets for Intra-Cellular Therapies
or view top-rated stocks among Wall Street analysts.

How has Intra-Cellular Therapies' stock performed in 2022?

Intra-Cellular Therapies' stock was trading at $52.34 at the beginning of 2022. Since then, ITCI shares have increased by 5.4% and is now trading at $55.17.
View the best growth stocks for 2022 here

When is Intra-Cellular Therapies' next earnings date?

Intra-Cellular Therapies is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022.
View our earnings forecast for Intra-Cellular Therapies

How were Intra-Cellular Therapies' earnings last quarter?

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) issued its earnings results on Tuesday, May, 10th. The biopharmaceutical company reported ($0.78) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.93) by $0.15. The biopharmaceutical company earned $35 million during the quarter, compared to analysts' expectations of $33.52 million. Intra-Cellular Therapies had a negative trailing twelve-month return on equity of 53.93% and a negative net margin of 294.89%. The firm's revenue was up 120.1% on a year-over-year basis. During the same period in the previous year, the business earned ($0.65) EPS.
View Intra-Cellular Therapies' earnings history

Who are Intra-Cellular Therapies' key executives?

Intra-Cellular Therapies' management team includes the following people:
  • Dr. Sharon Mates Ph.D., Co-Founder, Chairman, CEO & Pres (Age 69, Pay $2.25M)
  • Mr. Lawrence J. Hineline CPA, CPA, Sr. VP of Fin., CFO, Treasurer & Assistant Sec. (Age 66, Pay $791.01k) (LinkedIn Profile)
  • Mr. Michael I. Halstead J.D., Exec. VP, Gen. Counsel & Sec. (Age 49, Pay $1.08M)
  • Dr. Suresh K. Durgam M.D., Exec. VP & Chief Medical Officer (Age 53, Pay $1.03M) (LinkedIn Profile)
  • Mr. Mark Neumann, EVP & Chief Commercial Officer (Age 59, Pay $1.01M) (LinkedIn Profile)
  • Dr. Robert E. Davis Ph.D., Sr. VP & Chief Scientific Officer (Age 71)
  • Mr. Juan Fernando Sanchez, VP of Corp. Communications & Investor Relations (Age 51)
  • Ms. Karen Patruno Sheehy Esq., Sr. VP & Chief Compliance Officer (Age 60)
  • Dr. Michael Olchaskey, Sr. VP & Head of Regulatory Affairs
  • Mr. John A. Bardi, Sr. VP of Market Access, Policy & Gov. Affairs

What other stocks do shareholders of Intra-Cellular Therapies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Intra-Cellular Therapies investors own include Sorrento Therapeutics (SRNE), Amarin (AMRN), Gilead Sciences (GILD), CRISPR Therapeutics (CRSP), Synergy Pharmaceuticals (SGYP), Myovant Sciences (MYOV), Novavax (NVAX), Pfizer (PFE), AbbVie (ABBV) and Clovis Oncology (CLVS).

What is Intra-Cellular Therapies' stock symbol?

Intra-Cellular Therapies trades on the NASDAQ under the ticker symbol "ITCI."

How do I buy shares of Intra-Cellular Therapies?

Shares of ITCI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Intra-Cellular Therapies' stock price today?

One share of ITCI stock can currently be purchased for approximately $55.17.

How much money does Intra-Cellular Therapies make?

Intra-Cellular Therapies (NASDAQ:ITCI) has a market capitalization of $5.20 billion and generates $83.80 million in revenue each year. The biopharmaceutical company earns $-284.13 million in net income (profit) each year or ($3.630010) on an earnings per share basis.

How many employees does Intra-Cellular Therapies have?

Intra-Cellular Therapies employs 512 workers across the globe.

How can I contact Intra-Cellular Therapies?

Intra-Cellular Therapies' mailing address is 430 EAST 29TH STREET, NEW YORK NY, 10016. The official website for Intra-Cellular Therapies is www.intracellulartherapies.com. The biopharmaceutical company can be reached via phone at (464) 440-9333, via email at [email protected], or via fax at 646-440-9334.

This page (NASDAQ:ITCI) was last updated on 7/2/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.